Fierce Pharma December 27, 2024
The detention of several AstraZeneca employees and eventually the company’s China president Leon Wang unsettled investors, fueling fears of a crackdown similar to the GSK scandal 10 years ago.
Two parallel investigations are looking into AstraZeneca’s practices in China. An insurance fraud case originally publicized by the Chinese government in early 2022 centers around allegations of fabricated tumor test results to increase the number of eligible patients—and hence sales—for AZ’s EGFR lung cancer drug Tagrisso. Over the years, an increasing number of employees at AZ and its diagnostic partners have been implicated in the case.
The second and more recent probe involves alleged smuggling of unapproved drugs—the Daiichi-partnered HER2 therapy Enhertu and the cancer immunotherapy Imjudo—from Hong Kong to mainland...
Today's Sponsors
Today's Sponsor